FDA Approved Long-Acting Reversible Contraception

Note. Adapted from Ott MA, Sucato GS, Leroy-Melamed M, Hoopes AJ; American Academy of Pediatrics Committee on Adolescence. Contraceptive counseling and methods for adolescents: clinical report. Pediatrics. 2025;156(1):e2025072218. doi:10.1542/peds.2025-072218


References

Creinin MD, Schreiber CA, Turok DK, et al. Levonorgestrel 52 mg intrauterine system efficacy and safety through 8 years of use. Am J Obstet Gynecol. 2022;227(6):871.e1-871.e7. doi:10.1016/j.ajog.2022.05.022 

Creinin M, et al. A phase 3, multicenter, open-label study evaluating etonogestrel 68-mg contraceptive implant: initial efficacy and safety results in years 4 and 5 of extended use. Electronic poster 3465. Presented at 2026 ACOG Annual Clinical & Scientific Meeting; May 2, 2026. Accessed July 14, 2026. https://acog.multilearning.com/acog/2026/2026-acog-annual-clinical-and-scientific-meeting/4200256/mitchell.creinin.a.
phase.3.multicenter.open-label.study.evaluating.html

Nexplanon (etonogestrel implant) [package insert]. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021529s027lbl.pdf. Revised January 2026. Accessed July 14, 2026.

Ott MA, Sucato GS, Leroy-Melamed M, Hoopes AJ; American Academy of Pediatrics Committee on Adolescence. Contraceptive counseling and methods for adolescents: clinical report. Pediatrics. 2025;156(1):e2025072218. doi:10.1542/peds.2025-072218

These pathways do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at the time. It is impossible to anticipate all possible situations that may exist and to prepare a pathway for each. Accordingly, these pathways should guide care with the understanding that departures from them may be required at times.